New genetic evidence suggests that targeting GIPR and GLP1R could reduce harmful drinking patterns while improving liver and metabolic health, opening the door to repurposing existing metabolic drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback